clinical trial · NCT06927999
An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria
ARS Pharmaceuticals, Inc.·phase2·recruiting·n = 42
Urticaria ChronicPlacebo0.5 mg epinephrine1 mg epinephrine
brief summary
This is a Phase 2b, outpatient, single-dose, randomized, double blind, placebo-controlled, three period crossover study that will consist of a screening period and three blinded treatment periods. Subjects enrolled will have CSU with a history of moderate to severe acute exacerbations (or flares).
started
Jul 9, 2025
primary completion
Jun 1, 2026
completion
Jun 1, 2026
last updated
Oct 2, 2025
official title
An Outpatient, Randomized, Double-Blinded, Placebo-Controlled, Cross-Over Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol